Stay updated on PERSEUS1: Pembrolizumab in Advanced Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the PERSEUS1: Pembrolizumab in Advanced Prostate Cancer Clinical Trial page.

Latest updates to the PERSEUS1: Pembrolizumab in Advanced Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check9 days agoChange DetectedA banner announces an NIH transition in terminology, noting that agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check22 days agoChange DetectedThe footer’s displayed site revision advances from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe study record page now shows a 403 Forbidden error, indicating the page is currently inaccessible. This replaces the usual study details with an access-restriction message.SummaryDifference20%

- Check65 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, signaling a new release of the page template. No public content changes are indicated by the provided data.SummaryDifference0.1%

Stay in the know with updates to PERSEUS1: Pembrolizumab in Advanced Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PERSEUS1: Pembrolizumab in Advanced Prostate Cancer Clinical Trial page.